Literature DB >> 9576298

The safety and efficacy of stereotactic biopsy for intracranial lesions.

W A Hall1.   

Abstract

BACKGROUND: Stereotactic brain biopsy is considered by many physicians to have significant morbidity and mortality rates with a high risk of sampling error resulting in misdiagnosis. The technical aspects necessary to perform the procedure safely and effectively are unfamiliar to most physicians.
METHODS: After reporting his initial results with stereotactic brain biopsy, several modifications were implemented by the author to improve the morbidity, mortality, and diagnostic yield rates, including complex surgical planning with regard to patient selection, biopsy trajectory, imaging technique, target choice, and intraoperative pathologic review. The results of implementing these modifications were examined retrospectively in 134 consecutive brain biopsies.
RESULTS: One hundred and thirty-four stereotactic brain biopsies were performed in 122 patients. Computed tomography guidance was used in 85 patients (63%) and magnetic resonance imaging was used in 49 patients (37%). Sixty-four lesions (48%) were located in the right hemisphere, 61 (45%) in the left, and 9 (7%) in the midline. The most common diagnoses included 62 malignant brain tumors (46%), 24 benign brain tumors (18%), 23 neurologic disorders (17%), and 20 infections (15%). Five biopsies (4%) did not demonstrate a pathologic process for an overall diagnostic yield of 96%. Reasons for diagnostic failure included lesion location adjacent to the ventricular system, inaccurate targeting, and the inability to penetrate the tumor. One patient sustained a neurologic deficit after the biopsy for a morbidity rate of 0.7% and one sustained a fatal hemorrhage during the biopsy of a vascular tumor for a mortality rate of 0.7%. These results are comparable to those reported in 7471 biopsies (current series included) in which the morbidity rate was 3.5%, the mortality rate was 0.7%, and the diagnostic yield was 91%.
CONCLUSIONS: Stereotactic brain biopsy is an extremely safe and effective procedure for evaluating intracranial lesions. Complex surgical planning can decrease the risk of potential complications and the use of intraoperative pathologic examination can improve the diagnostic yield for this procedure.

Entities:  

Mesh:

Year:  1998        PMID: 9576298     DOI: 10.1002/(sici)1097-0142(19980501)82:9<1756::aid-cncr23>3.0.co;2-2

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  54 in total

1.  Strong 5-aminolevulinic acid-induced fluorescence is a novel intraoperative marker for representative tissue samples in stereotactic brain tumor biopsies.

Authors:  Georg Widhalm; Georgi Minchev; Adelheid Woehrer; Matthias Preusser; Barbara Kiesel; Julia Furtner; Aygül Mert; Antonio Di Ieva; Boguslaw Tomanek; Daniela Prayer; Christine Marosi; Johannes A Hainfellner; Engelbert Knosp; Stefan Wolfsberger
Journal:  Neurosurg Rev       Date:  2012-03-10       Impact factor: 3.042

2.  A review of perioperative complications during frameless stereotactic surgery: our institutional experience.

Authors:  Zulfiqar Ali; Hemanshu Prabhakar; Parmod K Bithal; Hari H Dash
Journal:  J Anesth       Date:  2009-08-14       Impact factor: 2.078

3.  Interstitial imaging with multiple diffusive reflectance spectroscopy projections for in vivo blood vessels detection during brain needle biopsy procedures.

Authors:  Fabien Picot; Andréanne Goyette; Sami Obaid; Joannie Desroches; Simon Lessard; Marie-André Tremblay; Mathias Strupler; Brian Wilson; Kevin Petrecca; Gilles Soulez; Frédéric Leblond
Journal:  Neurophotonics       Date:  2019-04-23       Impact factor: 3.593

4.  Stereotactic biopsy in elderly patients: risk assessment and impact on treatment decision.

Authors:  Stephanie G Kellermann; Christina A Hamisch; Daniel Rueß; Tobias Blau; Roland Goldbrunner; Harald Treuer; Stefan J Grau; Maximilian I Ruge
Journal:  J Neurooncol       Date:  2017-06-21       Impact factor: 4.130

5.  Real-time MR-guided brain biopsy using 1.0-T open MRI scanner.

Authors:  Xiangmeng He; Ming Liu; Chao Liu; Jing Fang; Yujun Xu; Ligang Wang; Jianfeng Xiang; Roberto Blanco Sequeiros; Chengli Li
Journal:  Eur Radiol       Date:  2018-06-12       Impact factor: 5.315

6.  Open biopsy in patients with acute progressive neurologic decline and absence of mass lesion.

Authors:  Albert J Schuette; Jason S Taub; Costas G Hadjipanayis; Jeffrey J Olson
Journal:  Neurology       Date:  2010-08-03       Impact factor: 9.910

7.  Brain biopsy in benign neurological disease.

Authors:  C E Gilkes; S Love; R J Hardie; R J Edwards; N J Scolding; C M Rice
Journal:  J Neurol       Date:  2012-02-24       Impact factor: 4.849

8.  The Combined Performance of ADC, CSF CXC Chemokine Ligand 13, and CSF Interleukin 10 in the Diagnosis of Central Nervous System Lymphoma.

Authors:  M C Mabray; R F Barajas; J E Villanueva-Meyer; C A Zhang; F E Valles; J L Rubenstein; S Cha
Journal:  AJNR Am J Neuroradiol       Date:  2015-09-17       Impact factor: 3.825

9.  Diagnostic challenges, management and outcomes of midline low-grade gliomas.

Authors:  Mueez Waqar; Shahid Hanif; Nitika Rathi; Kumar Das; Rasheed Zakaria; Andrew R Brodbelt; Carol Walker; Michael D Jenkinson
Journal:  J Neurooncol       Date:  2014-08-06       Impact factor: 4.130

10.  Towards improving the safety and diagnostic yield of stereotactic biopsy in a single centre.

Authors:  Ruben Dammers; Joost W Schouten; Iain K Haitsma; Arnaud J P E Vincent; Johan M Kros; Clemens M F Dirven
Journal:  Acta Neurochir (Wien)       Date:  2010-08-01       Impact factor: 2.216

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.